In a groundbreaking study published in Nature, researchers have elucidated the intricate structural mechanisms by which a novel nanobody, Nanosota-MB1, neutralizes the entry of Marburgvirus (MBV) into host cells. The findings offer unprecedented insight into the viral glycoprotein’s receptor-binding site (RBS) and open promising avenues for therapeutic intervention against Marburgvirus infections. This research presents a compelling molecular narrative that details how nanobody-based therapeutics could mimic host receptor interactions to block viral entry.
Central to the study is the trimeric glycoprotein of the Ravn virus (RAVV), a close relative of Marburgvirus, which facilitates viral entry into host cells by engaging the cellular Niemann-Pick C1 (NPC1) receptor. The structure of the RAVV GP-ΔM (a truncated glycoprotein) complexed with Nanosota-MB1 revealed that three nanobody molecules bind symmetrically to the trimer, each targeting a receptor-binding site. This precise engagement underscores the nanobody’s ability to firmly occlude the viral receptor interface.
Nanobodies are unique single-domain antibodies derived from camelids that consist of three complementarity-determining regions (CDRs) and four framework regions. The study identifies CDR2 and CDR3 of Nanosota-MB1 as the primary mediators of interaction with the RBS. Notably, CDR2 prominently inserts into a hydrophobic cavity within the RBS, using residues phenylalanine at position 58 (Phe58) and isoleucine at position 59 (Ile59). These residues establish strong hydrophobic contacts with key amino acids of the viral glycoprotein, including tryptophan 70 (Trp70), phenylalanine 72 (Phe72), and methionine 154 (Met154).
Fascinatingly, this binding posture mirrors that of the host receptor NPC1’s loop 2, which inserts into the same hydrophobic pocket during viral attachment. NPC1’s phenylalanines 503 and 504 (Phe503 and Phe504) interact with the RBS in a manner that the nanobody elegantly replicates. This molecular mimicry underpins the nanobody’s high binding affinity and illustrates a remarkable evolutionary convergence designed to obstruct receptor access directly.
To substantiate these structural observations, the researchers employed surface plasmon resonance (SPR) assays that demonstrated competitive binding between NPC1-C and Nanosota-MB1 to the RAVV GPcl, a cleaved form of the glycoprotein necessary for receptor interaction. When Nanosota-MB1 was bound first, subsequent addition of NPC1-C failed to engage the glycoprotein, confirming that the nanobody effectively competes for the receptor-binding site.
Complementing the binding studies, pseudovirus neutralization assays utilizing retroviruses bearing the full-length MBV glycoproteins showed that Fc-tagged Nanosota-MB1 exhibited potent neutralizing activity. This was evident across pseudoviruses derived from multiple Marburgvirus strains—including Ravn virus (RAVV), and two Marburg virus strains (Musoke and Angola). The inhibition was quantitatively assessed, with nanobody concentrations measured to establish half-maximal inhibitory concentration (IC50) values, thereby confirming its promise as a broad-spectrum antiviral agent.
This research offers a vivid molecular blueprint for designing nanobody-based therapeutics that exploit receptor mimicry to abrogate viral entry. The structural mimicry versus NPC1 receptor is particularly notable because it sheds light on viral vulnerability points that can be therapeutically targeted. Such insights are invaluable given the high fatality rates and limited treatment options associated with Marburgvirus infections.
The implications of this study extend into vaccine design, antiviral drug development, and therapeutic antibody engineering. By understanding the precise molecular interactions between viral glycoproteins and neutralizing agents, scientists can rationally design inhibitors that either prevent receptor binding or destabilize viral structure. Specifically, Nanosota-MB1 exemplifies how synthetic antibodies can be engineered to exploit naturally evolved receptor engagement mechanisms, introducing a novel paradigm in antiviral strategies.
Moreover, the crystallographic resolution achieved in the study reveals minute but critical details of hydrophobic pockets and residue-residue contacts that were previously uncharacterized. Such atomic-level insights empower the computational design of even more effective nanobody variants or small molecules that could bind the viral glycoprotein’s RBS.
Given the high mutation rates frequently observed in filoviruses, the use of structurally robust nanobodies that mimic conserved receptor contacts offers a promising route to circumvent viral escape mutations. This study provides foundational knowledge for such endeavors by highlighting conserved residues that are essential for receptor binding and thus less likely to mutate without compromising viral fitness.
In summary, the work of Ye et al. represents a significant advance in our understanding of Marburgvirus entry and neutralization. By integrating cryo-electron microscopy, biochemical assays, and neutralization experiments, the research delineates how nanobody therapy can be tailored for effective viral inhibition. This innovative approach holds the potential to deliver new countermeasures against one of the most lethal viral pathogens known to humankind.
As the world continues to grapple with emerging viral threats, these findings are a beacon of hope—offering not only a deeper mechanistic insight into viral-host interactions but also a tangible pathway toward next-generation antivirals. The structural sophistication harnessed in Nanosota-MB1 provides a template for the rational design of nanobody therapeutics with broad applications beyond Marburgvirus, potentially extending to other filoviruses and enveloped viruses.
Future research will undoubtedly build upon this work by exploring the in vivo efficacy, pharmacokinetics, and potential synergy of such nanobodies with existing antiviral treatments. Ultimately, this study lays the critical groundwork for translating structural biology into lifesaving medical interventions against Marburgvirus and related pathogens.
Subject of Research: Structural and biochemical characterization of the Marburgvirus glycoprotein and its neutralization by a nanobody mimicking the NPC1 receptor.
Article Title: Structures of Marburgvirus glycoprotein and its complex with NPC1 receptor.
Article References:
Ye, G., Bu, F., Turner-Hubbard, H. et al. Structures of Marburgvirus glycoprotein and its complex with NPC1 receptor. Nature (2026). https://doi.org/10.1038/s41586-026-10240-0
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41586-026-10240-0
Tags: complementarity-determining regions in nanobodieshydrophobic cavity binding in viral proteinsMarburgvirus glycoprotein structuremolecular basis of viral-host interactionnanobody camelid antibodiesnanobody-based antiviral therapeuticsNanosota-MB1 nanobody neutralizationNPC1 receptor bindingRavn virus glycoprotein trimerreceptor-binding site occlusiontherapeutic targeting of Marburgvirusviral entry inhibition mechanisms
